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Systemic drug testingSystemic repeated dose safety assessment and systemic efﬁcacy evaluation of substances are currently
carried out on laboratory animals and in humans due to the lack of predictive alternatives. Relevant inter-
national regulations, such as OECD and ICH guidelines, demand long-term testing and oral, dermal,
inhalation, and systemic exposure routes for such evaluations. So-called ‘‘human-on-a-chip’’ concepts
are aiming to replace respective animals and humans in substance evaluation with miniaturized func-
tional human organisms. The major technical hurdle toward success in this ﬁeld is the life-like combina-
tion of human barrier organ models, such as intestine, lung or skin, with parenchymal organ equivalents,
such as liver, at the smallest biologically acceptable scale. Here, we report on a reproducible homeostatic
long-term co-culture of human liver equivalents with either a reconstructed human intestinal barrier
model or a human skin biopsy applying a microphysiological system. We used a multi-organ chip
(MOC) platform, which provides pulsatile ﬂuid ﬂow within physiological ranges at low media-to-tissue
ratios. The MOC supports submerse cultivation of an intact intestinal barrier model and an air–liquid
interface for the skin model during their co-culture with the liver equivalents respectively at 1/100.000
the scale of their human counterparts in vivo. To increase the degree of organismal emulation, microﬂu-
idic channels of the liver–skin co-culture could be successfully covered with human endothelial cells,
thus mimicking human vasculature, for the ﬁrst time. Finally, exposure routes emulating oral and sys-
temic administration in humans have been qualiﬁed by applying a repeated dose administration of a
model substance – troglitazone – to the chip-based co-cultures.
 2015 Published by Elsevier B.V.osphate
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Strategies to develop ‘‘human-on-a-chip’’ platforms are apply-
ing microphysiological systems (MPS) to the in vitro combination
of miniaturized human organ equivalents into miniature func-
tional human organisms [1–4]. It has been widely accepted that
systems with at least ten organs are needed to assemble human
organismal homeostasis at a level of complexity comparable to
that of human or animal bodies. These aim to replace systemic
toxicity testing and efﬁcacy assessment of therapeutic agents, food
additives, chemicals, or environmental pollutants in laboratory
animals, and to predict human safety and efﬁcacy data prior to
substance exposure to humans [5]. Numerous microphysiological
‘‘organ-on-a-chip’’ devices have been developed and applied to
the culture of single organ tissues under dynamic conditions at
miniature scale, thus overcoming the artiﬁcial conditions of static
tissue cultures. Their main advantage lies in providing proper
dynamic mechanical and chemical cues to the tissues, thus emulat-
ing the real situation of the tissue microenvironment in vivo. They
have been reviewed extensively in the past [1,2,6]. However, up to
the present day, only a few multi-organ chip (MOC) concepts have
been translated into MPSs, combining several tissue types [7–11].
In addition to the physiological way of mechanically and chemi-
cally coupling each individual tissue, these devices use their
microﬂuidic channel systems to physically combine different
chip-based cell culture compartments with each other as a ﬁrst
engineering step toward organisms on a chip. The major technical
hurdle toward success in this ﬁeld is the life-like combination of
human barrier organ models with parenchymal organ equivalents
at the smallest biologically acceptable scale. Furthermore, human
cell lines in suspension or monolayers, rather than primary cells
and tissues with 3D architectures, are used to mimic organ tissues
in such systems. None of these existing multi-organ systems
address the challenges of air–liquid interfaces for barrier models,
such as skin or lung. Finally, all of these microphysiological
multi-organ systems lack the human endothelial cell coverage of
the microﬂuidic channels. Organs in the human body are intercon-
nected by a vascular network entirely lined by human endothelial
cells, representing nature’s blood-tissue barrier. The endothelial
cell layer communicates with the tissue and signals into the blood
stream to recruit, for example, leucocytes into a region of local
damage in the organism. Finally, a closed endothelial cell layer pre-
vents blood cells from bleeding into tissue and clotting. Different
approaches to establish human vasculature in vitro at a mini-scale
through the so-called BioVaSc technology [12–14] and at a micro-
scale on chips [15–18] have been published in the past. Such
endothelialization would be preferable to emulate the biological
impact of human vasculature on systemic organismal homeostasis
in microphysiological MOC systems. In order to overcome the
aforementioned challenges, we developed a novel MOC platform
allowing the culture of reconstructed parenchymal and barrier
organ equivalents or the respective biopsy tissues over long peri-
ods at a scale 100.000-fold smaller than the original organs. As a
proof of concept, we were able to demonstrate a stable four-week
homeostasis between human 3D liver spheroids, composed of
HepaRG cells and human primary stellate cells, and skin prepuce
biopsies in the microphysiological MOC system [19]. Moreover,
we developed a method to fully cover the microﬂuidic channel sys-
tem of our MOCs with human microvascular endothelial cells
under physiological pulsatile ﬂow conditions [18].
We here report, for the ﬁrst time, the application of the MOC
system for the co-culture of human 3D liver spheroids with a sec-
ond barrier model – human intestine – composed of primary
human intestinal epithelial cells. Furthermore, we improved the
established co-culture of liver spheroids and skin biopsies byendothelialization of the entire microchannel system of the chip,
mimicking human vasculature. Finally, we emulate systemic, oral
or dermal routes of repeated dose substance exposure in the two
co-cultures over an exposure time of nine to eleven days.2. Materials and methods
2.1. Design and fabrication of the microphysiological system
Multi-organ chips were produced, as described by Wagner et al.
[19]. In brief, a single polydimethylsiloxane (PDMS) layer, height
2 mm, containing the respective arrangement of channels, microp-
umps and openings for culture compartments was permanently
bonded to a glass microscope slide with a footprint of
75  25 mm (Menzel, Braunschweig, Germany) by low pressure
plasma oxidation (Femto; Diener, Ebhausen, Germany), thus form-
ing the respective ﬂuid-tight microﬂuidic MOC device with stan-
dard channel heights of 100 lm. The peristaltic on-chip
micropump was modiﬁed after Wu and co-workers [20], and
represents three 500 lm thick PDMS membrane valves in a row.
They are consecutively actuated by applying pressure. The
microﬂuidic layout of the MOC used in this study consisted of
two culture compartments per co-culture circuit (Fig. 1C). Each
culture compartment holds a maximum of 300 ll medium. The
direct exposure of tissue to ﬂuid ﬂow in the liver spheroid culture
compartment (left side) and the alternative co-culture setting in a
Transwell separating tissues from the ﬂuid ﬂow in the barrier
organ culture compartment (right side) by a porous polycarbonate
membrane (thickness 10 lm, pore size 0.4 lm) are highlighted.2.2. Management of microﬂuidics
The MOC platform provides a number of tools, e.g. pumping fre-
quency and peristaltic valve pressure, to adjust ﬂuid ﬂow and, con-
sequently, mechanical forces according to the physiology of the
respective organ equivalents. Microparticle imaging velocimetry
(lPIV) has been routinely established to set process parameters
for physiological MOC operation [18]. We improved the lPIV tech-
nology here so that it became biocompatible for measurements in
sterile, endothelial cell covered MOC circuits. Process parameters
supporting a median shear stress below 2 dyn cm2 in position A
of each microﬂuidic circuit (Fig. 1C) had to be selected [21]. This
would shield the liver equivalents in the subsequent culture com-
partment from high mechanical stresses. Human red blood cells
(RBCs) instead of synthetic polymeric particles were established
for that type of imaging velocimetry. In brief, human RBCs were
obtained from donors by venepuncture. Plasma was discarded
and the cells were suspended in 0.9% sodium chloride solution. A
hematocrit of 2.5% was chosen for the RBC imaging solution. An
amount of 300 ll of the solution was gently ﬁlled into each insert
area of the circuit of a fully endothelialized MOC. Subsequently, the
MOC was operated at different process regimens. The circulating
RBCs were recorded in a region of interest around position A by a
high-speed CMOS-camera (HXC40, Baumer) attached to a standard
inverted microscope (2.5magniﬁcation). At point A the cross sec-
tion of the channel was 100 lm high and 500 lm wide. The y-res-
olution was reduced to 112 px framing only the channel
boundaries to raise the frame rate above 2900 fps. The pixel size
was determined to be 4.32 lm px1. The RBC displacement was
analyzed in consecutive images by PIVlab [22,23] an open-source
tool for MATLAB. In order to derive only the maximum velocity
in the x-direction of the central part of the images, one quarter
was omitted on either side in the y-direction. Proﬁles of the pul-
satile ﬂow in position A were recorded (Fig. 1D). From this, a
Fig. 1. Tissue allocation and microﬂuidic proﬁling in the MOC. (A, B) Cross section of an assembled MOC schematically illustrating the liver–intestine co-culture (A) and liver–
skin co-culture (B) in the right-hand circuit of each MOC. Emulation of systemic substance exposure is illustrated in the liver compartment of A, while mimicry of oral
administration is shown on the intestine (B). (C) Clockwise and counterclockwise ﬂuid ﬂow within the two circuits is illustrated by bold arrows. Red blood cell assisted lPIV
measurements in position A of the microchannels at different process conditions support selection of optimal ﬂow conditions. (D) Example of a pulsatile ﬂow proﬁle of human
red blood cells in position A of an endothelialized MOC. Median ﬂow rates and median shear stress values were calculated on the basis of this proﬁle.
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gave rise to the median ﬂow rate and the median shear stress at
the channel walls in position A, eventually. Essential mathematics
have been described by us earlier [18]. Process parameters ensur-
ing a median shear stress of less than 0.7 dyn cm2 were identiﬁed
and set for the respective co-culture experiments.2.3. Cell and tissue sources
The human HepaRG cell line was obtained from Biopredic
International (Rennes, France). Human primary hepatic stellate
cells (HHSteC) were purchased from ScienCell Research
Laboratories (Carlsbad, CA, USA). Reconstructed human small
intestinal barrier models in cell culture inserts of the 96-well size
were constructed by MatTek Corporation (Ashland, MA, USA).
Human juvenile prepuce from 6 different donors of the age of
3–5 years was obtained from a pediatric surgery after routine cir-
cumcisions, with informed consent and ethics approval (Ethic
Committee Charité University Medicine, Berlin, Germany), in com-
pliance with the relevant laws. Skin biopsies and human dermal
microvascular endothelial cells (HDMEC) were derived from such
prepuce samples.2.4. Reconstruction of the intestine barrier model
Intestine barrier models, produced at MatTek Corporation, were
established using primary small intestine (SI) epithelial cells from
the ileum section of small intestine tissue obtained from a 19 year
old Caucasian female donor with no history of gastrointestinal dis-
ease. The tissues were obtained with informed consent. The cells
were screened for HIV, HBV, HCV and mycoplasma prior to use
and were found to be negative. Small intestinal epithelial cells
were harvested using enzymatic tissue dissociation and primary
cell culture techniques. The cells were expanded in culture and
seeded directly onto 96-well cell culture inserts, raised to the
air–liquid interface, and cultured using a specially formulated cul-
ture medium (MatTek Corporation) designed to induce differentia-
tion over a period of 14 days. The necessary amount of insert-based
intestinal barrier cultures was released for a two-day overseasshipment at 4 C after transepithelial electrical resistance (TEER)
levels reached a stable range of 50–180 O cm2 mimicking the
physiologic human SI microenvironment [24–26]. Upon reception,
the cell culture inserts were transferred into the respective number
of MOC systems. Insert-holders ensured a precise positioning of
the barrier models at a height of 100 lm above the bottom glass
slide of each MOC-circuit to ensure free media passage below the
intestinal barrier models.2.5. Preparation of the skin biopsy barrier
Prepuce sampleswith an average size of 2.5 cm2were stored and
transported in 10 ml phosphate-buffered saline (PBS) at 4 C and
prepared for further culturewithin 4 h following surgery. Theywere
subsequently incubated in 80% ethanol for 30 s. Samples with an
average thickness of 2 mm were punched to provide biopsies of
5 mm diameter. Samples were loaded with the epidermal-side up
into 96-well Transwell (Corning, Lowell,MA,USA) inserts andwere
then integrated into the respective MOC culture compartments.2.6. De novo formation of liver equivalents
Cell culture components were purchased from PAA Laboratories
(GE Healthcare Europe GmbH, Vienna, Austria) and cultures were
incubated at 37 C and 5% CO2, unless otherwise stated.
HepaRG cells were maintained, as described by Gripon et al.
[27]. Brieﬂy, cells were cultured in HepaRG medium, consisting
of William’s Medium E supplemented with 10% fetal calf serum,
100 units per ml penicillin, 100 lg ml1 streptomycin, 5 lg ml1
human insulin, 2 mM L-glutamine, and 5  105 M hydrocortisone
hemisuccinate (Sigma–Aldrich, St. Louis, MO, USA). Medium was
renewed every two or three days. Induction of differentiation
was initiated by maintaining the cells in growth medium for two
weeks in order to reach cellular conﬂuence, according to the manu-
facturer’s instructions. Differentiation medium containing 2%
dimethyl sulfoxide (DMSO; Carl Roth GmbH, Karlsruhe,
Germany) was then added for a cultivation period of two weeks.
When differentiation was completed, the cells were used for fur-
ther experiments. Human stellate cells were expanded in Stellate
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CA, USA), on poly-L-lysine-coated T75 tissue culture ﬂasks
(ScienCell). Cells were harvested for further use at 80% conﬂuence.
Human liver spheroids were formed combining HepaRG cells
and human stellate cells, as described previously [19], using
Perfecta3D 384-Well Hanging Drop Plates (3D Biomatrix, Ann
Arbor, MI, USA). Brieﬂy, 20 ll HepaRG medium containing
4.8  104 hepatocytes and 0.2  104 HHSteC was pipetted to each
access hole. After two days of hanging drop culture, spheroids were
transferred to ultra-low attachment 24-well plates (Corning).
Twenty spheroids were collected together to form a single liver
equivalent in the respective culture compartment of an MOC
insert, as described in Wagner et al. [19].
2.7. Isolation of endothelial cells
Human dermal microvascular endothelial cells were isolated
from prepuce samples as described previously by Schimek et al.
[18]. Brieﬂy, samples were cleaned in 80% ethanol, subcutaneous
tissue was removed and samples were incubated in 5 mg ml1 dis-
pase II solution (Sigma–Aldrich, Schnelldorf, Germany) at 4 C for
15–18 h. The dermis was subsequently incubated in 4 mg ml1
Collagenase NB 4 solution (Serva, Heidelberg, Germany) at 37 C
for 75 min. The cell solution was ﬁltered through a 70 lm nylon ﬁl-
ter (Corning, Lowell, MA, USA) and centrifuged at 300g for 5 min.
The resulting cell pellet was resuspended in Endothelial Cell
Growth Medium MV2 (ECGM-MV2; PromoCell, Heidelberg,
Germany) supplemented with Supplement-Pack MV2 (PromoCell,
Heidelberg, Germany), 1% penicillin–streptomycin and 0.05% fun-
gizone. The cells were seeded into a T-75 ﬂask and grown in 5%
CO2 at 37 C. Cells were puriﬁed by magnetic associated cell sorting
(MACS) twice for endothelial speciﬁc surface marker PECAM-1
(Miltenyi Biotec, Bergisch Gladbach, Germany), according to the
manufacturer’s instructions.
2.8. Endothelialization of multi-organ chips
Prior to seeding the endothelial cells into the MOC, each circuit
was ﬂushed with ECGM-MV2 and incubated statically for three
days in 5% CO2 at 37 C, as described by Schimek et al. [18]. The
HDMECs were harvested from expansion cultures and cell suspen-
sion was concentrated by centrifugation. Cell viability was >90% for
all experiments. Centrifuged cells were resuspended with complete
ECGM-MV2 to a ﬁnal concentration of 2  107 cells ml1.
Afterward, the cell suspension was injected through one of the
two compartments of each circuit into the system using a 1 ml syr-
inge. After even cell infusion into both circuits the device was incu-
bated in 5% CO2 at 37 C under static conditions for 3 h to allow the
cells to attach to the channel walls. An amount of 300 ll fresh med-
ium was added to each compartment and then ﬂushed through the
PDMS channels using the on-chip micropump of each circuit. A
frequency of 2 Hz was applied to the microvascular circuits of the
MOCs for continuous dynamic operation. The frequency was
deﬁned as the amount of pulses of the pump cycle per second.
2.9. Chip-based co-cultures
Ten MOC circuits were loaded with an intestine barrier insert
and liver equivalent and eight endothelialized MOC circuits were
loaded with a skin biopsy insert and a liver equivalent for subse-
quent co-culture. The height of the tissue and the amount of med-
ium added to the cell culture inserts enabled the tissues to be at
the air–liquid interface (skin) or submerged in media (intestine).
Co-cultures were cultured in 450 ll circulating medium, an
additional 50 ll of medium was added on top of intestinal tissues,
leading to a total volume of 500 ll in intestinal and liver tissuecultures and 450 ll in skin and liver co-cultures. 250 ll of this
medium was replaced daily and supernatants were collected to
determine the lactate release and the glucose consumption. At
the end of the fourteen-day co-culture, cell viability and protein
expression were analyzed by immunohistochemistry and qRT-
PCR techniques.
2.10. Model substance
We used troglitazone, a substance inducing metabolic activities
and, ﬁnally, toxicity in HepaRG cells, to challenge the co-cultures at
repeated dose regimens. Troglitazone (Sigma–Aldrich Chemie
GmbH, Munich, Germany) was dissolved in DMSO, stored frozen
at a concentration of 20 mM until use, and then diluted in culture
medium to a level of 0.05% DMSO. Medium containing 0.05% DMSO
was used for control cultures.
2.11. Oral exposure to liver–intestine co-cultures
Oral substance exposure to theMOC co-cultureswasmodeled by
administration of 50 ll of a 100 lM troglitazone solution into the
apical compartment of the tissue culture inserts on top of the
human intestinal barrier. A complete penetration of troglitazone
through the intestine, therefore, would result in a daily application
of a systemic concentration of 10 lM. The daily administration
started after a three-day administration-free adaptation period
and was performed over a period of 11 days. Experiments were ﬁn-
ished at day 14 and tissueswere removed from theMOC. Cell viabil-
ity and protein expressionwere assessed by immunohistochemistry
and qRT-PCR. All experiments were performed in quadruplicate.
2.12. Systemic exposure to liver–skin co-cultures
Systemic substance exposure to the MOC was modeled by dilut-
ing 2.5 ll of a 20 mM troglitazone solution in cell culture medium
and administering it to each MOC circuit, resulting in a ﬁnal sys-
temic concentration of 50 lM troglitazone. The daily treatment
started after a ﬁve-day administration-free adaptation period and
was performed over a period of nine days. Experiments were ﬁn-
ished at day 14 and tissueswere removed from theMOC. Cell viabil-
ity and protein expressionwere assessed by immunohistochemistry
and qRT-PCR. All experiments were performed in quadruplicate.
2.13. Co-culture analyses
Tissue metabolic activity was monitored daily by the measure-
ment of glucose and lactate in the media supernatants. Therefore,
the Glucose LiquiColor Oxidase kit (Stanbio Laboratory, Boerne,
USA) was used with minor modiﬁcations: An amount of 100 ll of
reagent was used and 1 ll of sample was added. Lactate concentra-
tion of the mediumwas measured using the LAC 142 kit (Diaglobal,
Berlin, Germany), according to the manufacturer’s instructions,
with minor modiﬁcations based on our own standard curves: An
amount of 99 ll of the reagent was mixed with 1 ll of sample
and absorbance was measured at 520 nm, using medium as a
reference.
Immunohistochemical end-point analyses were performed by
staining the tissue sections for cytokeratin 8/18, Von Willebrand
factor (vWF), vimentin, cytokeratin 10, cytokeratin 15, sodium–
potassium pump (NaK-ATPase), and multidrug resistance-associ-
ated protein 2 (MRP-2). Brieﬂy, representative central cryosections
of the tissues were ﬁxed in acetone at -20 C for 10 min and
blocked with 10% goat serum in PBS. Liver sections were then incu-
bated with mouse anti-human cytokeratin 8/18, rabbit anti-human
vimentin (both Santa Cruz Biotechnology, Heidelberg, Germany)
and rabbit anti-human vWF antibody (Abcam, Cambridge, UK)
Table 1
Primers used for RT-qPCR.
Gene Primer sequences (50–30)
Albumin F TGCAAGGCTGACGATAAGGAG
R TTTAGACAGGGTGTTGGCTTTACAC
Cyp 3A4 F GGAAGTGGACCCAGAAACTGC
R TTACGGTGCCATCCCTTGAC
BSEP F GCAGACACTGGCGTTTGTTG
R ATGTTTGAGCGGAGGAACTGG
MRP-1 F ACCTCATCCAGTCCACCATCC
R GGCCATGCTGTAGAAAAGACCTC
ZO-1 F TCTCGGAAAAGTGCCAGGAAG
R CCCTCGGAAACCCATACCAG
CPS-1 F CCCAGCCTCTCTTCCATCAG
R GCGAGATTTCTGCACAGCTTC
PPARa F ACAAGGTCAAAGCCCGGGTC
R AGCAGTGAAAGATGCGGACCT
MMP7 F TGGGGAACTGCTGACATCATGA
R TCCCTAGACTGCTACCATCCGT
PPARg F CCCAGGTTTGCTGAATGTGAAG
R GAAGGGAAATGTTGGCAGTGG
MUC 2 F CCGACCTCCAGCACAGTTTT
R GATCCTTGACCGACCTGCAC
NaK-ATPase F ACAGCCCAGAAATCCCAAAAC
R CAGCGGTCATCCCAGTCC
SLC5A1 F GAGCCCAGCAACTGTCCCAC
R CAGGCTCCAACACAGACGGT
Villin F GGCCTCTGCCCATCTTCC
R AGGTTTTGTTGCTTCCATCGAG
TBP F CCTTGTGCTCACCCACCAAC
R TCGTCTTCCTGAATCCCTTTAGAATAG
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594 and goat anti-rabbit IgG Alexa Fluor 488 (all purchased from
Life Technologies, Darmstadt, Germany) were used for visualiza-
tion. Skin tissues were stained for mouse anti-human cytokeratin
10 (Merck-Millipore, Darmstadt, Germany) and rabbit anti-human
cytokeratin 15 (Abcam). Small intestinal epithelial tissue sections
were stained for rabbit anti-human NaK-ATPase (Abcam), mouse
anti-human Cytokeratin 8/18 and rabbit anti-human MRP-2 (both
Santa Cruz Biotechnology). Staining procedures were the same as
for the liver tissue. Goat anti-rabbit IgG Alexa Fluor 594 and goat
anti-rabbit FITC (both purchased from Life Technologies) were
used for visualization of skin and intestinal tissues.
Furthermore, apoptosis and proliferation were analyzed by
immunohistological end-point stainings at the end of each MOC
experiment using TUNEL (TdT-mediated dUTP-digoxigenin nick
end labeling)/Ki67 markers. Brieﬂy, representative eight-micron
cryostat central sections of the tissue were stained for apoptosis
using the TUNEL technique (ApopTag1 Peroxidase In Situ
Apoptosis Detection Kit, Merck Millipore, Darmstadt, Germany),
according to the manufacturer’s instructions. The apoptosis stain-
ing was combined with a nuclear stain, Hoechst 33342 (Life
Technologies), the antibody Ki67 (rabbit anti-human, Abcam) and
its respective secondary antibody (goat anti-rabbit IgG Alexa
Fluor 594, Life Technologies).
Real-time qPCR endpoint analyses were performed to evaluate
gene transcription at mRNA level after the MOC cultures were
stopped. Therefore, tissue equivalents were collected for RNA iso-
lation using the RNeasy Mini Kit (Qiagen, Hilden, Germany).
cDNA was synthesized by reverse transcription of 400 ng total
RNA (TaqMan1, Roche Diagnostics, Mannheim, Germany). Real-
time qPCR experiments were conducted using the Stratagene sys-
tem (Agilent Technologies, Böblingen, Germany) and the
SensiFast SYBR No-ROX One-Step Kit (Bioline, Luckenwalde,
Germany), according to the manufacturer’s instructions. The real-
time qPCR primers are shown in Table 1.
2.14. Transepithelial electrical resistance
The barrier function of the small intestinal epithelial tissue was
monitored by TEER using the Millicell ERS-2 Volt-Ohm Meter
(Millipore Co., Bedford, USA) and was monitored at the beginning
of the experiment and at the last day of experiment. Millicell
inserts were removed from the MOC for the measurement and
TEER analysis was performed, as described by the manufacturer.
TEER was expressed as X cm2 based on the area of transwell plate
inserts after subtracting the resistance of the supporting ﬁlter from
the reading and multiplying it by the surface area of the
monolayer.
2.15. Liquid chromatography-tandem mass spectrometry analysis of
troglitazone
LC-MS/MS analysis of troglitazone from media supernatants
was performed using a modular HPLC system (pump: LC-20AD,
Shimadzu, Duisburg, Germany) coupled to a QTRAP5500 mass
spectrometer (AB Sciex, Darmstadt, Germany). Chromatographic
separation was achieved using an OTU LipoMare C18 column
(150  4.6 mm; 5 lm; Application & Chromatography,
Oranienburg, Germany). The injection volume was 10 lL and the
mobile phase ﬂow rate was 500 lL min1. Mobile phase A con-
sisted of water and mobile phase B of methanol. Gradient elution
was achieved by ramping from 40% B to 90% B within 10 min, fol-
lowed by a holding step at 90% B for 3 min and subsequent re-
equilibration. All samples were diluted 1:500 and syringe ﬁltrated
(0.2 lm, nylon) prior to injection. For MS/MS detection negative
electrospray ionization multiple-reaction monitoring mode wasused. Curtain gas was maintained at 35 psi. Optimized ion spray
voltage was 4000 V and the source temperature was 500 C.
Quantiﬁer ion transition was m/z 440? 397, qualiﬁer ion transi-
tions were m/z 440? 145 and m/z 440? 117.
2.16. Statistical analysis
Statistical analysis of the data was performed by t-test follow-
ing the Welch test to determine signiﬁcant differences among
means using GraphPad software (Prism 6). Differences were con-
sidered signiﬁcant at p < 0.05. Data are expressed as the mean of
four independent experiments performed in quadruplicate.
3. Results and discussion
The MOC platform presented here enables the integration of
biological barriers into dynamic multi-tissue system. The microﬂu-
idic design consists of an on-chip micropump reproducibly operat-
ing a circulation system interconnecting two organ culture
compartments, each the size of a single well of a standard 96-well
microplate. The integration of industrially available cell culture
inserts allows the cultivation of tissues at an air–liquid or liquid–
liquid interface. Well-established tissue models of, for example,
human skin, intestine and lung can be integrated into the MOC,
enabling a mechanical coupling and molecular crosstalk of the tis-
sues with secondary organs. The secondary organ, e.g. a liver
equivalent, can be placed into the second culture compartment.
The widening of the channels in the culture compartments reduces
the shear stress and the ﬂuid ﬂow in the culture area, avoiding the
ﬂushing of the tissues. To assure that the tissues do not get ﬂushed
away during peristaltic pumping, daily microscopic inspection was
performed. Fig. 1A depicts an exemplary experimental set-up of a
liver–intestine co-culture and Fig. 1B the experimental set-up of
a skin-liver co-culture. Substance application for drug testing can
be performed either systemically, by applying the substance
directly to the media circuit, or apically, on the intestine. It could
be demonstrated by lPIV using RBCs, that in position A (Fig. 1C)
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exceed 0.7 dyn cm2 at pump frequencies of 2 Hz, resulting in a
median ﬂow rate of 2.6 ll min1. Therefore, the on-chip microp-
ump was set at a 2 Hz frequency over the whole period of the
respective experiments.
3.1. Fourteen-day performance of liver-intestinal co-cultures in the
MOC
Current intestinal in vitro tests are based on monolayer cultures
of immortalized cell lines, mainly Caco-2, HT-29 or T84 cell lines
obtained from human colorectal adenocarcinomas. However,
immortalized cell lines do not recapitulate the 3D small intestine
tissue architecture and show a 100-fold difference in pharmaceuti-
cal permeability coefﬁcients compared to in vivo intestinal epithe-
lium [28]. Therefore, the drug metabolism and absorption of these
intestine models do not represent the in vivo situation correctly. In
addition to using primary cells, it was shown recently that a
dynamic microenvironment is critical to elicit in vivo-like physio-
logical responses [29]. Therefore, in this study, a human primary
small intestinal equivalent was combined with a liver equivalent
in the microﬂuidic circuit of our MOC. The liver and primary intes-
tine equivalents were kept viable in this co-culture for 14 days. The
cultures were sustained by 500 ll medium which was partially
replaced every 24 h.
The small intestine model showed columnar epithelial cell mor-
phology similar to in vivo human small intestine and had a height
of up to 140 lm. Exposure to a higher pressure and an additionalFig. 2. Performance of liver–intestine co-cultures in MOCs over 14 days. Staining for
epithelial tissue. (B) MRP-2 (red) expression in small intestinal epithelial tissues. (C) T
intestinal epithelial tissues. (D) Equal distribution of HHSteC, stained with vimentin (r
stained with DAPI (blue). (For interpretation of the references to colour in this ﬁgure leﬂow on the apical side of the intestinal tissue increased the height
of columns to 250 lm in an intestinal-mono-culture (data not
shown). In vivo, proliferating cells are located in the crypt base
and give rise to proliferating progenitor cells which migrate
upward. Consistently, most proliferating cells (positive for Ki67)
in the cultured intestinal tissue were located at the lowest layer,
with only few proliferating cells at upper levels (Fig. 2A).
Conventional CaCo-2 monolayers cultured in transwells have been
reported to have unphysiologic tight junctions and therefore too
high TEER values (TEER 300–600 O cm2) compared to physiologic
TEER values ranging from 50 to 120 O cm2 in human small and
large intestine [24,25]. In comparison, our primary intestinal
epithelial tissues could keep a constant close to physiologic TEER
values during the 14-day culture in the MOC (starting with TEER
values of 50–180 O cm2 and ending with TEER values of 70–
180 O cm2). In Caco-2 cells, the expression of the ABC membrane
transporter superfamily in immuno-histology staining could not
be observed under static conditions [13]. In comparison, we could
detect the expression of MRP-2 in our intestinal tissues (Fig. 2B).
However, a polarization of the intestinal tissue could not be
achieved and MRP-2 is expressed in every cell of the tissue. The
inﬂuence of a different medium on the apical and the basolateral
side of the tissue and a second perfusion on the luminal side of
the tissue, might help to initiate a polarization as seen by Schanz
et al. [13] on the example of MDR-1. Immunoﬂuorescence staining
revealed the expression of active transporter pumps, such as the
sodium–potassium pump (Fig. 2C). Cytokeratin 8/18 expression
proves their epithelial origin. The liver tissues still showed a(A) TUNEL/Ki67 showing apoptosis (green) and viability (red) in small intestinal
ransporter NaK-ATPase (red) and epithelial cells cytokeratin 8/18 (green) in small
ed), within hepatocytes, stained with cytokeratin 8/18 (green). (A–D) Nuclei were
gend, the reader is referred to the web version of this article.)
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14 days of dynamic co-culture. No alterations in cell ratios or mor-
phology could be observed.
3.2. Fourteen-day performance of liver–skin co-cultures in
endothelialized MOCs
Liver equivalents and skin punch biopsies were co-cultivated in
endothelialized MOCs under dynamic conditions for up to 14 days.
Primary human endothelial cells isolated from two patients were
seeded at a density of 2 x 107 cells ml1 into the channels of the
MOC seven days prior to adding the liver and skin tissue models
to allow the establishment of a fully endothelialized microﬂuidic
circuit. The endothelial cells covered all surfaces of the channel cir-
cuit (Fig. 3A) and produced a conﬂuent monolayer (Fig. 3B), even
after 14 days of dynamic co-culture, representing 21 days ofFig. 3. Performance of liver–skin co-cultures in endothelialized MOCs over 14 days. (A) Ca
the microﬂuidic circuit. (B) Higher magniﬁcation view of HDMEC monolayer. (C) HDMEC
vWF (green) staining of HDMECs. (D) Skin biopsy stained for cytokeratin 15 (red) and
stained with Hoechst (blue). Scale bars 100 lm. (E) Glucose and lactate metabolic a
interpretation of the references to colour in this ﬁgure legend, the reader is referred toculture in the MOC. In total, 105 endothelial cells, 106 liver cells
and a skin biopsy of 5 mm, having a volume of about 24 ll and con-
sisting of 5  106 skin cells, were co-cultivated in one microﬂuidic
circuit of the MOC. These cell numbers are within the physiological
range and represent roughly 1/100.000 of the size of the respective
counterpart organ in the human body. The cultures could be sus-
tained at steady state conditions by a total medium volume of
500 ll per MOC circuit and a daily medium exchange rate of 50%.
An interaction of the endothelial cells with the liver equivalents
was observed by immunoﬂuorescence staining showing an
integration of the cells between liver spheroids in areas where they
were in direct cell–cell contact (Fig 3C). However, these interac-
tions were limited to the contact surface of the spheroids with
the underlying monolayer of endothelial cells and did not show
any measurable effects on the expression of liver-typical markers
(data not shown). Skin punch biopsies showed a retainedlcein AM staining (red) showed viable and evenly distributed HDMECs in all areas of
-liver tissue interaction shown by cytokeratin 8/18 (red) staining of hepatocytes and
cytokeratin 10 (green) showing a preserved continuous layer of cells. Nuclei were
ctivity of co-cultures of skin, liver and endothelial cells over 14 days. (For the
the web version of this article.)
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10 in keratinizing and non-keratinizing stratiﬁed epithelia respec-
tively after 14 days of culture (Fig. 3D). The continuous layer of
cells observed in the stratum basale and the overlying differ-
entiated keratinocytes of the epidermis hint at the preservation
of an elementary barrier function of this model. However, the
punch biopsy and the supporting cell culture insert do not form
a tight connection with each other, allowing for a penetration of
substances which would be applied topically into the underlying
media circuit. An improvement of the model is envisaged by gluing
the biopsy into the insert using ﬁbrin or other extracellular matrix
components. The integration of tissue models that were generated
in porous inserts and can be purchased from various suppliers
holds another possibility for a deﬁned and tight skin barrier model
to analyze effects of topical applied substances in co-culture with a
second organ. Overall metabolic activity of the three-tissue co-cul-
tures, measured as glucose consumption and lactate production,
was stable with only minor ﬂuctuations from day six until the
end of culture, indicating a stable artiﬁcial coexistence between
the tissues (Fig. 3E).
3.3. Repeated dose substance exposure to MOC co-cultures
Troglitazone was chosen as a model substance to optimize and
qualify MOC-based administration regimens equivalent to oral and
systemic exposure in humans. It belongs to the thiazolidinedione
class of compounds representing a family of drugs used for the
treatment of noninsulin-dependent type 2 diabetes mellitus. The
ﬁrst commercialized thiazolidinedione drug, troglitazone (trade
name: Rezulin), was withdrawn from the U.S. market after numer-
ous reported cases of severe idiosyncratic liver damage and failures
leading to liver transplantation or death. Troglitazone is rapidly
absorbed with an absolute bioavailability of between 40% and
50% [30]. During clinical trials, troglitazone was administeredFig. 4. Performance of liver and small intestinal epithelial tissue co-cultures in MOCs afte
tissue for transporter NaK-ATPase (red) and cytokeratin 8/18 (green). (B) Staining of sm
qRT-PCR data of liver tissues from control (normalized to 1) and treated co-cultures anal
and ZO-1. (D) qRT-PCR data of small intestinal tissues from control (normalized to 1) and
ATPase, SLC5A1, Villin, and ZO-1. (A and B) Nuclei were stained with DAPI (blue). Scale ba
p 6 0.05. (For the interpretation of the references to colour in this ﬁgure legend, the reaorally at a daily concentration of up to 600 mg per patient. In pre-
vious studies, troglitazone was shown to also affect the metabo-
lism of HepaRG cells in vitro [31,32]. This sensitivity provides an
additional measurement of substance distribution to the liver
equivalents in our co-cultures. In order to reach a reproducible
homeostasis in the MOC system, a three-day administration-free
adaptation period is mandatory for the liver–intestine co-culture,
while the liver–skin co-culture requires a ﬁve-day adaptation
phase prior to administration of troglitazone. The selection of vari-
ous troglitazone doses in the co-culture experiments was guided
by following general assumptions: A 100.000-fold downscale of
the daily patient doses corresponds to 6 lg (10 lM) for oral
administration in the MOC. Taking into account the bioavailability,
an average concentration of 5 lM is expected to be a physiological
range in the systemic circulation of the MOC.
3.4. Modeling oral exposure to the liver–intestine co-culture
A reproducible and easy to perform oral substance administra-
tion protocol was performed over a stretch of 11 days after a three-
day administration-free adaptation period, resulting in a continu-
ous two-week MOC performance at repeated dose testing condi-
tions. Oral substance exposure to the MOC co-cultures was
modeled by administration of the respective troglitazone solution
into the apical compartment of the tissue culture inserts on top
of the human intestinal barrier at a high concentration to ensure
detectable effects on the liver equivalents. The substance needs
to penetrate the barrier of the intestinal tissue and to be pumped
to the second compartment of the MOC in order to reach the liver
equivalent. TEER levels of the intestinal tissues treated ranged from
70 to 180 O, while control values ranged from 98 to 194 O.
Therefore, no signiﬁcant decrease in barrier function of the intesti-
nal barrier was observed compared to the control. The treatment of
the troglitazone showed a decrease in albumin mRNA expressionr 11 days of chronic troglitazone exposure. (A) Staining of small intestinal epithelial
all intestinal epithelial tissue for the ATP-dependent export pump MRP-2 (red). (C)
yzed for expression of Albumin, BSEP, CPS1, Cyp3A4, MMP7, MRP-1, PPARa, UGT1A1
treated co-cultures analyzed for expression of CYP3A4, PPARg, MRP-1, MUC2, NaK-
rs 100 lm. (C and D) Data are mean ± SD of four independent co-cultures. ⁄Indicates
der is referred to the web version of this article.)
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synthase 1 (CPS-1), a mitochondrial enzyme which transforms
ammonia and bicarbonate to carbamoyl phosphate, a ﬁrst step in
the urea cycle to remove excess urea from cells, decreased. The
mRNA expression of CYP 3A4 increased (Fig. 4C), indicating an
increased metabolic biotransformation from troglitazone to qui-
none and epoxide metabolites. These data correlate with data
observed with liver single cultures [33,34] and prove that troglita-
zone passed the intestinal barrier, was pumped to the liver tissue
and was then metabolized. In previous studies UGT 1A1 has been
shown to exhibit low troglitazone glucuronosyltransferase activi-
ties [35]. In human liver microsomes, troglitazone did not inhibit
bilirubin conjugation at a concentration of 100 lM or less [36].
This correlates to the data of our study, showing a slight, but
non-signiﬁcant increase of UGT1A1 mRNA expression after the
chronic application of 10 lM troglitazone. The bile salt export
pump (BSEP) mRNA expression did not change signiﬁcantly but
showed a high variance in our experiments. BSEP is involved in
maintaining bile acid homeostasis in the liver. In isolated canalicu-
lar rat liver plasma membrane preparations, troglitazone competi-
tively inhibited the ATP-dependent taurocholate transport,
mediated by BSEP [37]. In contrast, it has been shown that trogli-
tazone increases BSEP mRNA expression signiﬁcantly in Huh7 liver
cells after single dose application [38], while metabolites of trogli-
tazone are known to reduce the mRNA expression of BSEP in
in vitro cultured hepatocytes [39]. This might explain the high vari-
ance of expression after 7 day chronic application, where troglita-
zone as well as its metabolites might have inﬂuenced the
expression of BSEP mRNA expression. MRP-1 and ZO-1 expression
did not change after treatment with troglitazone (Fig. 4C). ToFig. 5. Performance of liver–skin co-cultures in endothelialized MOCs after exposure to t
treated as control or (B) exposed to 50 lM troglitazone. Scale bars 300 lm. (C) qRT-PCR
Albumin, Cyp3A4, BSEP, MRP-1, ZO-1 and CPS-1. Data are mean ± SD of four indepen
supernatants of respective single tissue and co-cultures over time. MOC Li: liver single t
endothelial single-tissue culture in the MOC; and MOC Li-Va-Sk: respective three-tissueaccess liver toxicity it would be helpful to analyze ALT and AST
as liver speciﬁc lysis markers in the medium. However, the
sensitivity of existing tests needs to be optimized in the coming
year, in order to allow the measurement at relevant low levels.
In addition to the response of the liver equivalent, we also
observed some reactivity in the human organotypic intestinal bar-
rier. The mRNA expression of CYP 3A4 decreased after treatment,
in contrast to the increased levels in the liver tissue (Fig. 4D).
The mRNA expression of NaK-ATPase decreased on (Fig 4 D).
Similar to the data observed in the liver, MRP-1 and ZO-1 expres-
sion in the intestine barrier did not change during troglitazone
treatment (Fig. 4D). Immunoﬂuorescence staining could not
observe any changes in NaK-ATPase, Cytokeratin 8/18 or MRP2
expression, showing no effect on the polarization of the tissue
(Fig. 4A and B). To the best of our knowledge, there are no other
comparable data available in the literature of such effects of trogli-
tazone on human intestine, which makes the system as an interest-
ing research tool in this ﬁeld. Finally, troglitazone treatment also
reduced the expression of SGLT1 mRNA, but had no effect on
PPAR-gamma, correlating to studies performed in rats [40].
3.5. Modeling systemic exposure to the liver–skin co-culture
A reproducible and easy to perform systemic substance
administration protocol was performed over a stretch of nine days
after a ﬁve-day administration-free adaptation period resulting in
a continuous two-week MOC performance at repeated dose testing
conditions. Systemic substance exposure to the MOC was modeled
by administration of the respective troglitazone solution into the
liver spheroid culture compartment of each MOC circuit. Here,roglitazone. TUNEL/Ki67 staining of liver equivalents from co-cultures that were (A)
data of liver tissues from control and treated co-cultures analyzed for expression of
dent co-cultures. ⁄Indicates p 6 0.05 (D) Troglitazone concentration in the media
issue culture in the MOC; MOC Sk: skin single tissue culture in the MOC; MOC Va:
co-cultures.
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concentration in patients, to ensure the induction of metabolic
effects within the liver equivalent both on mRNA and protein
expression levels. Interestingly, the response was less pronounced
than expected from earlier studies with 5 lM troglitazone in non-
endothelialized co-cultures [19]. An increase in hepatocellular
necrosis was detected in the cultures treated, demonstrated by
TUNEL/Ki67 staining (Fig. 5A and B). Furthermore, an increase
on the cytochrome P450 3A4 expression level was observed on
the mRNA level (Fig. 5C), matching previous ﬁndings of an upregu-
lated biotransformation activity following troglitazone treatment
[19]. Troglitazone values in the media supernatants of the co-cul-
ture compared to respective single-tissue MOC cultures indicated
that most of the substance was taken up by the tissues during
the ﬁrst days of treatment (Fig. 5D). It has been reported previously
that troglitazone distributes extensively to various body tissues.
The highest concentrations were reported to be in the liver, gas-
trointestinal tract and fat [30]. The uptake especially in the skin
biopsies containing small amounts of fatty tissue underneath was
observed in this study. Cultures containing liver equivalents also
showed a reduction of troglitazone concentration in the media
supernatants at the beginning of treatment, even though it was
less prominent than in co-cultures containing skin biopsies. This
might be due to the size difference between the respective tissue
models. Skin biopsies had a mean volume of 24 ll, whereas liver
equivalents had a volume of only 1–2 ll. The troglitazone concen-
tration of liver single-tissue cultures and liver-endothelial co-cul-
tures was similar (data not shown) and was always about 10 lM
below the concentration of endothelial single-tissue cultures in
the MOC, indicating that that this might be the concentration
metabolized by the HepaRG cells every day. In the case of troglita-
zone, vascularization was not necessary to avoid penetration into
PDMS, as can be seen in Fig 5D: The total concentration of troglita-
zone in the medium in endothelial cell single-cultures, was 100%
shortly after application. The culture of skin and liver showed a
minimal decrease of troglitazone compared to the same culture
with endothelial cells only in the ﬁrst day of application and was
equal in all following days. Thus, in our setting, a penetration of
troglitazone into the PDMS with and without endothelial cells is
minimal and can be ignored in this study.4. Conclusions
Fourteen-day co-cultures of human 3D liver equivalents with
human intestinal barriers, on the one hand, and skin biopsies, on
the other hand, have successfully proven the capability of the
microphysiological MOC system to reliably and reproducibly inter-
connect a parenchymal organ equivalent with various human bar-
rier organ models. The MOC design assists a direct exposure of the
liver equivalent to low shear stress, while shielding the human bar-
rier organs from shear stress by industrial standard microporous
insert membranes. The latter mode, in addition, facilitates the
exposure of skin to the air–liquid interface. The co-cultures, oper-
ated at a total on-chip volume of 500 ll medium at recirculation
rates of 2.6 ll min1, stabilized at a metabolic steady state at day
three for liver–intestine co-cultures and at day ﬁve for liver–skin
co-cultures with an endothelialized microchannel system.
Furthermore, the co-cultures sustained a repeated dose troglita-
zone exposure mimicking an oral administration route for the
liver–intestine co-cultures and a systemic administration route
for the endothelialized liver–skin co-culture. In both cases, the
liver equivalents responded properly to the respective troglitazone
challenge, as demonstrated at the mRNA and immunohistochem-
istry level. Interesting insights into histoarchitecture and meta-
bolic reactivity of the barrier organs investigated could be gainedregarding the homeostatic co-cultures. The stable maintenance of
an entirely endothelialized microchannel system on the liver–skin
MOCs and the successful establishment of the ﬁrst in the literature
red blood cell assisted lPIV measurement marked a milestone
toward blood-perfused microphysiological MOCs. Finally, to the
best of our knowledge, the troglitazone exposed liver–intestine
co-cultures represent the ﬁrst report of a long-term performance
of a human primary columnar-like 3D epithelial barrier layer in
microphysiological systems. The main advantage of this MOC, is
the possibility to culture two organ equivalents together in one
system, where metabolites can be forwarded from one organ to
another by a pulsatile ﬂow. This enables interactions and crosstalk
between the two organs. Barrier models can be inserted into the
MOC for topical or apical application of substances to the system
before reaching the second organ. Additionally, the effect of absor-
bance from one organ (e.g. the skin and its adipose tissue) can be
taken into account. This may alter the available concentration of
the substance in the medium, compared to the applied dose.
Substance metabolites of one organ might have a different effect
on the second organ than the initial substance applied, resulting
in a different, but more precise outcome than in single cultures.
Taken together, the MOC allows a more complex analysis of the
effect on organs after substance exposure.
To summarize, our ﬁndings suggest that the MOC platform is
capable of comprehensively maintaining various miniaturized
human organ equivalents over long culture periods. Cells of differ-
ent origin (i.e. primary cells, biopsies and cell lines) can be cul-
tured, allowing a wide variety of applications. However, in order
to standardize the system, iPS cells from the same donor, differ-
entiated into different speciﬁc tissues, will be the most promising
tissue source. This will also facilitate immune compatibility. MOC
co-cultures can be exposed reproducibly to pharmaceutical sub-
stances at regimens and administration routes relevant to respec-
tive guidelines currently used for subsystemic substance testing in
animals. In-depth analysis of the yet undeﬁned ﬂuid ﬂow charac-
teristics of the tissue culture compartments at current device
geometries is ongoing to ground a fundamental understanding of
the robust long-term stability of the liver and skin tissue co-cul-
tures reported here.
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